Published: Wed, June 06, 2018
Medical | By Marta Holmes

Men with untreatable prostate cancer could halt its spread and live longer

Men with untreatable prostate cancer could halt its spread and live longer

African-American men with advanced prostate cancer might be more responsive than white men to an anti-androgen drug and steroids, according to a study led by Duke Cancer Institute researchers.

In addition, he said, "This research shows that by providing equal access to treatment, we can reduce racial disparities in outcomes for men with advanced prostate cancer".

Yes! Now the prostate cancer patients with hardly weeks or months to live will be able to survive longer if they are subjected to proper immunotherapy treatment. There are 47,000 new prostate cancer diagnoses annually in the United Kingdom alone, resulting in 11,000 deaths a year. Prostate cancer can develop when cells in the prostate start to grow in an uncontrolled way. Black patients experienced higher rates of several hormonal-based toxicities, such as hyperglycemia, hypokalemia, and hot flashes, "suggesting perhaps a greater exposure risk to this medicine", George said.

More news: Fred Completes Manchester United Move, Signs Five Year Contract

With researchers hinting that immunotherapy works best in patients with heavily mutated cancers, there is a strong chance that the therapy will not work on all prostate cancer patients.

While only 5% of men in the trial saw their tumours shrink or disappear after treatment, many of those had mutations in genes involved in repairing DNA in their tumours. It is an IgG4 isotype antibody that blocks a protective mechanism of cancer cells, and allows the immune system to destroy those cancer cells.

"Our examine has discovered that immunotherapy can profit a subset of males with superior, in any other case untreatable prostate most cancers, and these are most definitely to incorporate sufferers who've particular DNA restore mutations inside their tumours".

More news: Diego Maradona Messi was advised to "just enjoy the game"

Only around 20% of cancer patients respond to immunotherapy and researchers do not fully understand why. More white patients than black patients had no PSA decline.

"One of the major challenges with immunotherapy is that we don't have many reliable tests to pick out who will benefit", added Professor Paul Workman, chief executive of The ICR.

Professor Bono concludes, "This new trial has found that testing for mutations in DNA fix genes could be a valuable marker of who will respond".

More news: Russian space capsule with 3 crew lands in Kazakhstan

"If we can prove that in the planned new trial, it should be possible to provide some men with advanced prostate cancer with an exciting new treatment option". Prostate cancer is treated in a number of ways, but the more extreme treatments which include surgical interventions may cause physical and psychological side effects.

Like this: